{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-24T04:44:33.834Z","profile":{"slug":"dulaglutide","name":"Dulaglutide","aliases":[],"category":"GLP-1 receptor agonist"},"synthesis":{"mechanism":"Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes. WPF organizes the available work by glycemic outcomes, cardiovascular outcomes, comparisons, and safety. Results depend on the population, comparator, dose, and follow-up period.","evidence":"WPF’s existing Dulaglutide research atlas contains deduplicated source records and featured studies. Its featured REWIND randomized trial (PMID 31189511) studied major cardiovascular outcomes in people with type 2 diabetes and reported a lower incidence of its primary composite outcome over a median 5.4 years. The atlas also contains comparative work, including a network meta-analysis (PMID 38699397); indirect comparisons should not be treated as direct head-to-head trials. Proposed source ranks and tiers are discovery aids, not approved clinical conclusions.","safety":"This Directory entry has not yet promoted its screening inventory into a fully source-linked editorial synthesis. The REWIND composite outcome and study population should be stated precisely when interpreting its findings. The absence of published citations in this Directory lane reflects its editorial workflow, not the absence of research.","observationalBoundary":"WPF’s observational archive collects de-identified, self-reported experiences separately from clinical studies. Such reports can suggest research questions, but cannot establish causation, benefit, comparative safety, or event frequency.","openQuestions":"How do outcomes vary by baseline cardiovascular risk and other patient characteristics? Which comparative conclusions rest on direct randomized trials, and which rely on indirect synthesis? What do controlled studies establish about long-term safety and patient-relevant outcomes? These questions require source-level appraisal and explicit limits."},"completion":{"version":"wpf-profile-v1.1","verifiedSourceCount":0,"evidenceDepth":"limited_evidence","complete":false,"checks":[{"key":"overview","passed":true,"actual":272,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":565,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":342,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":237,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":348,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"evidence_depth_target","passed":false,"actual":0,"required":25,"severity":"warning"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":false,"actual":false,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":false,"actual":0,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["verified_sources","evidence_depth_target","reviewed_sources","chemistry","regulatory_context","claims"]},"chemistry":null,"evidence":[],"regulatory":[],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}